Novo Adds Lexicon’s Novel Obesity Drug To Deal Flurry

 
• By Andrew McConaghie
  
Lexicon
The Novo deal has lifted Lexicon's shares after a difficult few months of setbacks. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Start-Ups & SMEs